MDSpire - Summary
Feature

It's Like PCR, But Better

Geoff Smith introduces the mcPCR method for methylated DNA analysis that is expanding the potential of epigenetics for disease detection

Share

mcPCR, showcased at AGBT 2026, revolutionizes molecular pathology by enabling PCR for methylation analysis. Traditional PCR fails to capture crucial methylation signals necessary for disease diagnosis, particularly in cancer. mcPCR overcomes this by integrating a proprietary methyltransferase step, allowing for the amplification of both methylation patterns and genetic sequences. This innovation promises to enhance disease detection, particularly in low-input scenarios typical in early detection settings, ultimately benefiting patient care through less invasive monitoring methods.

Original Source(s)

It's Like PCR, But Better

  • by Helen Bristow

  • March 31, 2026

Related Content

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

  • by

  • March 31, 2026

  • 3 min